Why Multimerize?
Monomeric antigens can be poorly immunogenic, and its multimerisation can confer single shot seroconversion and better Ab responses, due to improved drainage to lypmh nodes and certain VLPs packaging TLR adjuvants.
Furthermore oriented antigen display can produce better quantitative and qualitative Abs than random display.
Why use Site-Specific Conjugation to Multimerize?
Use our technology to orient the display of any antigen or agonist of choice onto a nanoparticle for improved outcome. Our technology is simple, fast and robust, accelerating the research and development pipeline of your Prophylactic or Therapeutic Vaccine strategies.
Provide oriented antigen display needed for efficient B-cell receptor cross-linking
No inter cross-linking of nanoparticles
No chemical modification of internal residues
Our Locations
Genie Biotech Ltd.
St.Saviour
Jersey
JE2 7LA, UK
Tel: +44 (0) 1409 331154
UAB Genie Biotech EU
Santariškių g. 5,
Vilnius
08406, Lithuania
Tel: +37 (0) 52144617
Products & Services
Applications
Events
Upcoming Events:
BIO International Convention 2024: San Diego
3rd June 2024 – 6th June 2024
Previous Events:
BIO International Convention 2023: Boston
5th June 2023 – 8th June 2023